In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.

Cytokinetics finds a new partner in Greater China for its potential blockbuster drug — it could be one of a handful of ...

The site, which will be in the Beijing Economic and Technological Development Zone, will be Sanofi’s fourth production and supply base in China, Sanofi said in its official WeChat account.

As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights to the cardiovascular candidate. The rights will be transferred from ...

Sanofi is increasing its R&D presence in China, announcing plans to open a global research hub focused on data analysis in Chengdu. The French firm said this confirms China as the “third pillar ...

This will be Sanofi's largest single investment in China since entering the country in 1982. Sanofi has not been alone throughout this year in ramping up its commitment to the Chinese market. In the ...

China's economy demonstrated remarkable resilience and adaptability in 2024, amid complex domestic and global landscapes. The ...

CORXEL, formerly Ji Xing, in 2020, acquired the rights to develop and commercialize aficamten in Greater China from Cytokinetics. Sanofi will now acquire CORXEL's rights relating to aficamten in ...

Under the Health Silk Road, Beijing has embedded itself as a critical partner across Africa’s entire healthcare ecosystem, ...

China's economy demonstrated remarkable resilience and adaptability in 2024 amid complex domestic and global landscapes. The ...